Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib, Venetoclax, and Azacitidine in Blast Phase CML
NCT06757855Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in chronic myeloid leukemia blast phase (CML-BP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2025; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia blast phase (CML-BP)
Beyond the preview
Go deeper on NCT06757855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757855.